Antibody to granulocyte macrophage colony-stimulating factor reduces the number of activated tissue macrophages and improves left ventricular function after myocardial infarction in a rat coronary artery ligation model

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 5, 2011, Pages 568-574

  Kellar, Robert S ^a,d   Lancaster, Jordan J ^b   Thai, Hoang M ^b   Juneman, Elizabeth ^b   Johnson, Nicholle M ^b   Byrne, Howard G ^b   Stansifer, Maribeth ^b   Arsanjani, Reza ^b   Baer, Mark ^c   Bebbington, Christopher ^c   Flashner, Michael ^c   Yarranton, Geoffrey ^c   Goldman, Steven ^a  

^a Development Engineering Sciences   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c Kalobios   (United States)

^d NONE   (United States)

Author keywords

activated macrophages; antibody; GM CSF; granulocyte macrophage colony stimulating factor; left ventricular function; myocardial infarction

Indexed keywords

COLLAGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 518; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CORONARY ARTERY LIGATION; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HISTOCHEMISTRY; LEFT CORONARY ARTERY; MACROPHAGE ACTIVATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CELL COUNT; CELL MOVEMENT; CORONARY VESSELS; DISEASE MODELS, ANIMAL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMODYNAMICS; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MYOCARDIAL INFARCTION; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 79957687825     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318213258b     Document Type: Article

References (56)

1. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997; 337:1360-1369 (Pubitemid 27467771)
2. Weber KT, Pick R, Silver MA, et al. Fibrillar collagen and remodeling of dilated canine left ventricle. Circulation. 1990;82:1387-1401
3. Volders PG, Willems IE, Cleutjens JP, et al. Interstitial collagen is increased in the non-infarcted human myocardium after myocardial infarction. J Mol Cell Cardiol. 1993;25:1317-1323 (Pubitemid 24003838)
4. Anderson KR, Sutton MG, Lie JT. Histopathological types of cardiac fibrosis in myocardial disease. J Pathol. 1979;128:79-85 (Pubitemid 10226200)
5. Anversa P, Olivetti G, Capasso JM. Cellular basis of ventricular remodeling after myocardial infarction. Am J Cardiol. 1991;68:7D-16D
6. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med. 1997;336:1131-1141
7. Tan LB, Jalil JE, Pick R, et al. Cardiac myocyte necrosis induced by angiotensin II. Circ Res. 1991;69:1185-1195
8. Weisman HF, Bush DE, Mannisi JA, et al. Global cardiac remodeling after acute myocardial infarction: a study in the rat model. J Am Coll Cardiol. 1985;5:1355-1362 (Pubitemid 15069508)
9. Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201-1206 (Pubitemid 26117714)
10. Testa M, Yeh M, Lee P, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 1996;28:964-971 (Pubitemid 26348163)
11. Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 1995;92:1479-1486
12. Deswal A, Petersen NJ, Feldman AM, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103:2055-2059 (Pubitemid 32373007)
13. Maekawa Y, Anzai T, Yoshikawa T, et al. Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction: a possible role for left ventricular remodeling. J Am Coll Cardiol. 2002; 39:241-246 (Pubitemid 34084628)
14. Hong YJ, Jeong MH, Ahn Y, et al. Relationship between peripheral monocytosis and nonrecovery of left ventricular function in patients with left ventricular dysfunction complicated with acute myocardial infarction. Circ J. 2007;71:1219-1224 (Pubitemid 47195336)
15. Gasson JC. Molecular physiology of granulocyte-macrophage colonystimulating factor. Blood. 1991;77:1131-1145
16. Tanimoto A, Murata Y, Wang KY, et al. Monocyte chemoattractant protein-1 expression is enhanced by granulocyte-macrophage colony- stimulating factor via Jak2-Stat5 signaling and inhibited by atorvastatin in human monocytic U937 cells. J Biol Chem. 2008;283:4643-4651
17. Kohno Y, Tanimoto A, Cirathaworn C, et al. GM-CSF activates RhoA, integrin and MMP expression in human monocytic cells. Pathol Int. 2004 Sep;54:693-702 (Pubitemid 39297295)
18. Parissis JT, Adamopoulos S, Venetsanou KF, et al. Clinical and neurohormonal correlates of circulating granulocyte-macrophage colonystimulating factor in severe heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2000;86:707-710, A9-A10
19. Postiglione L, Montagnani S, Ladogana P, et al. Granulocyte macrophage-colony stimulating factor receptor expression on human cardiomyocytes from end-stage heart failure patients. Eur J Heart Fail. 2006;8:564-570 (Pubitemid 44572962)
20. Naito K, Anzai T, Sugano Y, et al. Differential effects of GM-CSF and G-CSF on infiltration of dendritic cells during early left ventricular remodeling after myocardial infarction. J Immunol. 2008;181:5691-5701
21. Maekawa Y, Anzai T, Yoshikawa T, et al. Effect of granulocyte- macrophage colony-stimulating factor inducer on left ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol. 2004; 44:1510-1520 (Pubitemid 39303957)
22. Raya TE, Gay RG, Aguirre M, et al. The importance of venodilatation in the prevention of left ventricular dilatation after chronic large myocardial infarction in rats: a comparison of captopril and hydralazine. Circ Res. 1989;64: 330-338
23. Gaballa M, Raya TE, Goldman S. Large artery remodeling after myocardial infarction. Am J Physiol. 1995;268:H2092-H2103
24. Raya TE, Gaballa M, Anderson P, et al. Left ventricular function and remodeling after myocardial infarction in aging rats. Am J Physiol. 1997; 273(pt 2):H2652-H2658
25. Goldman S, Raya TE. Rat infarct model of myocardial infarction and heart failure. J Card Fail 1995;1:169-177
26. Pennock GD, Raya TE, Bahl JJ, et al. Combination treatment with captopril and the thyroid hormone analog 3,5-diiodothyroproprionic acid (DITPA): a new approach to improving left ventricular performance in heart failure. Circulation. 1993;88:1289-1298 (Pubitemid 23264050)
27. Gaballa MA, Goldman S.Ventricular remodeling in heart failure. J Card Fail 2002;6:S476-S485, 2002 (Pubitemid 36083100)
28. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53:31-47 (Pubitemid 34020764)
29. Frangogiannis NG, Youker KA, Rossen RD, et al. Cytokines and the microcirculation in ischemia and reperfusion [Review]. J Mol Cell Cardiol. 1998;30:2567-2576 (Pubitemid 29017498)
30. Mehta JL, Li DY. Inflammation in ischemic heart disease: response to tissue injury or a pathogenetic villain? [Review] Cardiovasc Res. 1999;43: 291-299 (Pubitemid 29356367)
31. Buschmann IR, Hoefer IE, van Royen N, et al. GM-CSF: a strong arteriogenic factor acting by amplification of monocyte function. Atherosclerosis. 2001;159:343-356 (Pubitemid 33127248)
32. Coxon A, Tang T, Mayadas TN. Cytokine-activated endothelial cells delay neutrophil apoptosis in vitro and in vivo. A role for granulocyte/ macrophage colony-stimulating factor. J Exp Med. 1999;190:923-934
33. Frangogiannis NG. The mechanistic basis of infarct healing. Antioxid Redox Signal. 2006;8:1907-1939 (Pubitemid 46504897)
34. Murakami Y, Kurosaki K, Matsui K, et al. Serum MCP-1 and VEGF levels are not affected by inhibition of the renin-angiotensin system in patients with acute myocardial infarction. Cardiovasc Drugs Ther. 2003; 17:249-255 (Pubitemid 37421742)
35. de Lemos JA, Morrow DA, Sabatine MS, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003;107:690-695 (Pubitemid 36222595)
36. Parissis JT, Adamopoulos S, Venetsanou KF, et al. Serum profiles of C-C chemokines in acute myocardial infarction: possible implication in postinfarction left ventricular remodeling. J Interferon Cytokine Res. 2002;22:223-229 (Pubitemid 34275490)
37. Dewald O, Zymek P, Winkelmann K, et al. CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts Circ Res. 2005;96:881-889 (Pubitemid 40604972)
38. Hayashidani S, Tsutsui H, Shiomi T, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2003;108:2134-2140 (Pubitemid 37337591)
39. Simpson PJ, Todd RF III, Fantone JC, et al. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti- Mo1, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest. 1988 81:624-629 (Pubitemid 18075262)
40. Simpson PJ, Todd RF III, Mickelson JK, et al. Sustained limitation of myocardial reperfusion injury by a monoclonal antibody that alters leukocyte function. Circulation. 1990;81:226-237 (Pubitemid 20031787)
41. Cleutjens JP, Kandala JC, Guarda E, et al. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 1995;27:1281-1292
42. Peterson JT, Li H, Dillon L, et al. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res. 2000;46:307-315 (Pubitemid 30204603)
43. Trueblood NA, Xie Z, Communal C, et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res. 2001;88:1080-1087 (Pubitemid 34137122)
44. Whittaker P, Boughner DR, Kloner RA. Role of collagen in acute myocardial infarct expansion. Circulation. 1991;84:2123-2134
45. Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106:55-62 (Pubitemid 30437240)
46. Rohde LE, Ducharme A, Arroyo LH, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 1999;99:3063-3070 (Pubitemid 29270438)
47. Wu L, Tanimoto A, Murata Y, et al. Induction of human matrix metalloproteinase-12 gene transcriptional activity by GM-CSF requires the AP-1 binding site in human U937 monocytic cells. Biochem Biophys Res Commun. 2001;285:300-307 (Pubitemid 32918070)
48. Kohno Y, Tanimoto A, Cirathaworn C, et al. GM-CSF activates RhoA, integrin and MMPexpression in human monocytic cells. Pathol Int. 2004; 54:693-702 (Pubitemid 39297295)
49. Armitage JO. Emerging applications of recombinant human granulocyte- macrophage colony-stimulating factor. Blood. 1998;92:4491-4508 (Pubitemid 29005850)
50. Honkoop AH, Hoekman K, Wagstaff J, et al. Continuous infusion or subcutaneous injection of granulocyte-macrophage colony stimulating factor: increased efficacy and reduced toxicity when given subcutaneously. Br J Cancer. 1996;74:1132-1136 (Pubitemid 26333919)
51. Knoops S, Groeneveld ABJ, Kamp O, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) decreases left ventricular function. An echocardiographic study in cancer patients. Cytokine. 2001;14:184-187 (Pubitemid 32579328)
52. Yeghiazarians Y, Khan M, Angeli FS, et al. Cytokine combination therapy with long-acting erythropoietin and granulocyte colony stimulating factor improves cardiac function but is not superior than monotherapy in a mouse model of acute myocardial infarction. J Card Fail. 2010;16: 669-678
53. Zbinden S, Zbinden R, Meier P, et al. Safety and efficacy of subcutaneousonly granulocyte-macrophage colony-stimulating factor for collateral growth promotion in patients with coronary artery disease. J Am Coll Cardiol 2005;46:1636-1642 (Pubitemid 41531615)
54. Hill JM, Syed MA, Arai AE, et al. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol. 2005;46:1643-1648 (Pubitemid 41531616)
55. Wilson RF, Henry TD. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: double-edged swords. J Am Coll Cardiol 2005;46:1649-1650 (Pubitemid 41531617)
56. Anderlini P, Przepiorka D, Champlin R, et al. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood. 1996;88:2819-2825 (Pubitemid 26357361)